Top Tech Companies (721)
Don't see your company?
Create a company profile
OncoFusion Therapeutics is engaged in the R&D of personalized therapeutics for patients with genetically defined cancers.
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170 countries worldwide. Anton Paar is the world market leader in the field of density measurement, the determination of dissolved CO2 and the analysis of materials’ deformation and flow behavior. Customers of Anton Paar include the largest international soft drink producers and breweries, petroleum and food companies, the chemical and pharmaceutical industries, Formula 1 racing teams and many more. Our innovation builds on research and development, but goes beyond technology and involves all of Anton Paar’s employees. Innovation is the art of finding answers before the question is asked. Customers deserve reliable application solutions which are precise, economic and easy to use. Anton Paar customers can always expect more.
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorder and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit: • Focus on patient needs to drive decisions • Seek the wisdom of the team • Believe that people’s actions are well intended • Care enough to coach • See it, own it, make it happen • Demonstrate honesty and integrity at all times
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations. Headquartered in Pennsylvania, IPS is a multinational company with over 1,800 professionals and 23 offices in 10 countries in the United States, Canada, Brazil, the United Kingdom, Ireland, Germany, Switzerland, Singapore, China, and India. With the newest acquisition of Linesight, IPS has over 3,000 professionals in 45+ offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. Linesight specializes in cost, schedule, risk, program, and project management services in various market sectors, including data centers, life sciences, and high-tech industrial.
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs.
SmartAnalyst is focused on supporting Bio-Pharma Innovation, with a mission to drive pipeline and portfolio value for global pharmaceutical and biotech companies. We provide Consulting services, Health Economic and Real World Evidence solutions, and Insights that are compelling, strategic and actionable. Founded in 2000 and a part of the UDG Healthcare group since 2018. Our three pillars of Strategy, Value and Insights are aimed at identifying and commercializing novel innovative therapies to improve patient outcomes and garner market success, providing compelling clinical and cost benefit evidence to secure advantageous reimbursement and access to patients, and data driven insights into future market dynamics to develop forward looking strategies for clinical differentiation and success. We have worked across all major therapeutic areas including oncology, immunology, neurosciences, cardiovascular and rare diseases. Oncology is the cornerstone of our consulting business.
Airway Therapeutics focuses on pulmonary research program of Cincinnati Children’s Hospital Medical Center for further development.
iCeutica provides technology that fuels new product development by enabling meaningful clinical benefits and creating new intellectual property protection.
Seragon is a research-based biopharmaceutical company, committed to innovating cutting-edge discoveries in biotechnology and medicine.
.jpeg)
.png)
Helios Medical Communications is a full-service, independent, global healthcare communications and strategic consultancy agency. We specialise in delivering high-quality, high-impact bespoke solutions to meet our clients’ needs. Our core services include: · Strategic medical communications consultancy · Medical education · Publications and medical writing · External expert strategy and collaboration · Internal training solutions (MSL and brand) · Meetings · Multichannel communications · Patient-centric communications · Creative branding and design Our Core Values People Our people are our greatest asset. Our team is highly experienced, enthusiastic and committed to delivering the highest possible standards. Perspective We design and implement bespoke creative and intelligent solutions, drawn from our many years of experience, to help our clients reach their goals. Passion We are passionate about what we do. We bring energy to each project, and have a proactive, ‘can do’ attitude. Partnership To deliver the best results for our clients, we believe that developing long-term partnerships, built on a foundation of trust, respect and integrity, is key.
Erimos Pharmaceuticals is a biopharmaceutical company
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Siragen Pharmaceuticals is an innovative biotechnology company.
At Padagis our focus is on health care products that improve people’s lives. We are experts on extended topical products and are strategically investing to expand our #1 position in the extended topical category in the United States. Our team members, numbering more than 1,300 work in a dynamic environment where opportunity is built on a foundation of honesty and transparency.
Noxilizer provides room temperature NO2-based sterilization technology for the medical device, pharmaceutical and hospital industries.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
MediciNova is a biopharmaceutical company that acquires and develops novel, small-molecule therapeutics.
Accord Healthcare is a large-scale provider of generic pharmaceuticals in the United States. Our U.S. headquarters is in Durham, North Carolina, near the Research Triangle Park (RTP). Situated in a 7,000-acre pine forest, RTP is one of the largest research parks in the world. Close to three major research universities, the area provides an unparalleled scientific, regulatory, quality, and commercial talent pool. Accord is the commercial arm of Intas Pharmaceuticals, a pioneering biopharmaceutical company operating in India since 1976. Selling in over 75 countries, Accord has a vast global presence. The Accord and Intas networks provide full integration in the functional areas vital to delivering quality excellence and service efficiencies: API and finished dosage form manufacturing, R & D, clinical program management, and the economies of scale inherent in worldwide distribution. Accord is routinely cited in IQVIA presentations to industry as one of the fastest growing pharmaceutical companies in the U.S. Quarter-over-quarter, we consistently accomplish double-digit growth across all the metrics: in dollar sales, scripts filled, and number of units sold. We have accomplished this while undergoing multiple plant expansions across all of our manufacturing sites. Our solid record of maintaining high quality standards while implementing strategic commercial expansion has set us apart in the industry. Accord’s product offerings and pipeline demonstrate our commitment to meeting the needs of healthcare professionals and patients alike. We currently have approval for more than 115 ANDAs and are selling over 290 dosing presentations. We have 52 ANDAs pending at the FDA, and over 115 products in active development. Our pipeline spans a full range of dosage forms: orals, topicals, transdermal patches, liquid, lyophilized and complex injectables.
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer.
